Life Biosciences Reports First ER-100 Clinical Data

Clinical Report: Life Biosciences Reports First ER-100 Clinical Data

Overview

At the 2026 AAO Glaucoma Subspecialty Day, Life Biosciences’ chief scientific officer presented preliminary findings from the first 3 participants in the lowest-dose glaucoma cohort of the ER-100 trial. The company reported that treatment was well tolerated, with no adverse events or dose-limiting toxicities, and described improvement across a number of Humphrey visual field points.

Background

ER-100 is Life Biosciences’ first clinical candidate from its Epigenetic Restoration platform and is being studied in optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The Phase 1 trial is designed to evaluate safety and tolerability, with additional endpoints assessing visual function. Current European Glaucoma Society guidance identifies intraocular-pressure reduction as evidence-based care and states that evidence is insufficient to recommend neuroprotective agents for glaucoma. ER-100 remains an investigational therapy being evaluated in a clinical trial.

Data Highlights

Measure	Reported finding	Population or context
Participants	3	Glaucoma cohort; lowest ER-100 dose
Tolerability	Well tolerated; no adverse events or dose-limiting toxicities reported	First 3 participants presented
Visual function	Improvement across a number of visual field points	Humphrey visual field testing; preliminary report

Key Findings

Sharon Rosenzweig-Lipson, PhD, Life Biosciences’ chief scientific officer, presented the initial ER-100 findings at Eyecelerator during the 2026 AAO meeting.
The reported safety and visual field findings came from the first 3 participants in the glaucoma cohort treated at the lowest dose.
Life Biosciences reported no adverse events or dose-limiting toxicities in these participants and characterized ER-100 as well tolerated.
Humphrey visual field testing showed reported improvement across a number of points; the source provides no numerical effect estimate or further outcome details.
The Phase 1 trial evaluates ER-100 safety and tolerability, with additional endpoints assessing visual function, in optic neuropathies including open-angle glaucoma and NAION.
The European Glaucoma Society’s 6th edition guidance states that intraocular-pressure reduction remains evidence-based care and that evidence is insufficient to recommend neuroprotective agents in glaucoma.

Clinical Implications

These preliminary observations are limited to 3 participants at the lowest dose and do not establish treatment efficacy or characterize safety in a larger population. ER-100 is being evaluated in a clinical trial; the cited European guidance does not recommend neuroprotective agents for routine glaucoma care because evidence is insufficient.

Conclusion

The first reported ER-100 data describe preliminary tolerability and Humphrey visual field findings in 3 participants in the lowest-dose glaucoma cohort. Further trial data are needed to characterize the therapy’s safety and visual-function outcomes.